The Nebraska Attorney General’s Office announced on Friday around $720 million nationwide in settlements with eight drug makers that manufactured opioid pills. All eight defendants have agreed to ...

Red-light devices are all over social feeds and make enormous promises. From the many, we find the few that are actually worth your commitment, time, and money.

Eight drugmakers agreed to put legal claims stemming from their roles in the U.S. | Viatris, Hikma, Amneal, Apotex, Indivior, ...

The main purpose of this paper is to present a system designed to facilitate the distribution of pills to people in need and the work of medical staff with the help of technology. The project consists ...

Discover reviews, ratings, and trailers for P.O. Box Tinto Brass on Rotten Tomatoes. Stay updated with critic and audience scores today!

Using Scattering Matrix Analysis Method (SMAM), a high-power pill-box-type window without ghost mode is designed and simulated with a VSWR less than 1.1 in its ...

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary endpoints in a second Phase III trial.

We share the best gifts we've received lately, including some fishy earrings, blueberry napkins, and cozy clogs.

Home Helpful community members share ideas for what to do with empty pill bottles: 'I'm not alone in amassing a bunch of those' "Ours takes them (clean and without labels) and uses them to dispense ...

(RTTNews) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus on close objects.

Aktien » Nachrichten » VIATRIS AKTIE » Viatris Inc.: Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia Push Mitteilungen ...

PITTSBURGH, June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating ...